Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970 | Director | June 03, 2026 | June 04, 2026 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | 10% owner | December 11, 2025 | February 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LEXICON PHARMACEUTICALS, INC.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,995,498 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Exercise / conversion · Acquired 89,312 · Balance 1,995,498 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-06-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-03 · Exercise / conversion · Disposed 89,312 · Balance 0 F1: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2: Each restricted stock unit represents a contingent right to receive one share of common stock. |
| Common StockSEC Table I · non-derivative | IndirectBy Avicenna Life Sci Master Fund LP and related parties | 1,538,462 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,538,462 |
| Common StockSEC Table I · non-derivative | IndirectBy Invus Public Equities, L.P. and related parties | 7,362,368 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,362,368 |
| Common StockSEC Table I · non-derivative | IndirectBy Invus US Partners, LLC and related parties | 5,451,204 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,451,204 |
| Common StockSEC Table I · non-derivative | IndirectBy Invus, L.P. and related parties | 35,402,689 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 35,402,689 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.
F2: Each restricted stock unit represents a contingent right to receive one share of common stock.
Scholar Rock Holding Corp
Report date December 11, 2025 · Filed February 06, 2026
Jointly reported with Invus Global Management, LLC, Siren, L.L.C.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,825,013 |
Reported balance
After 2025-12-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-12-11 · Other · Acquired 1,575,008 · Balance 10,825,013 F1: The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane. F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.35 · Expires 2025-12-31 | Direct | 0 |
Reported balance
After 2025-12-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-11 · Other · Disposed 1,575,008 · Balance 0 F1: The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane. F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane.
F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Blue Buffalo Pet Products, Inc.
Report date April 24, 2018 · Filed April 24, 2018
Section 16 reporting ended · disclosed 2018-04-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-04-24 transaction · row 1
1 source rowRow 1 · 2018-04-24 · Disposition to issuer · Disposed 10,569 · Balance 0 F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").
F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes.
CRESCENT BIOPHARMA, INC.
Report date August 07, 2024 · Filed August 09, 2024
Jointly reported with Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Siren, L.L.C., Invus Global Management, LLC
Section 16 reporting ended · disclosed 2024-08-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,317,565 |
Last balance in matching sequence
After 2024-08-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-08-07 · Sale · Disposed 61,488 · Balance 6,578,438 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.175 to $0.1855 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Row 2 · 2024-08-08 · Sale · Disposed 260,873 · Balance 6,317,565 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.18 to $0.1978 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C.
F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.175 to $0.1855 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.18 to $0.1978 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
WW INTERNATIONAL, INC.
Report date May 09, 2023 · Filed May 11, 2023
Section 16 reporting ended · disclosed 2023-05-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 134,387 |
Reported balance
After 2023-05-09 transaction · row 1
1 source rowRow 1 · 2023-05-09 · Grant · Acquired 835 · Balance 134,387 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 4, 2026 20:09 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 89,312 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062822-26-000102 · form4.xml · derivative · entry 6 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 89,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 20:09 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 89,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001062822-26-000102 · form4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,995,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:09 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 43,478 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001062822-26-000067 · form4.xml · derivative · entry 2 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,478 Underlying: Common Stock · 43,478 shares Expires 2036-05-01 F3 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:09 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 35,714 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062822-26-000067 · form4.xml · derivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,714 Underlying: Common Stock · 35,714 shares Expires not disclosed F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 13:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 2,000 | $1.49 | $2,980.00 |
DisclosureSEC source: 0001062822-26-000033 · form4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,906,186 Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 12:00 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 100,000 | $1.47 | $147,000.00 |
DisclosureSEC source: 0001062822-26-000032 · form4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,904,186 Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 12:49 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 100,000 | $1.48 | $147,790.00 |
DisclosureSEC source: 0001062822-26-000031 · form4.xml · nonDerivative · entry 2 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,804,186 F2 · price: Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.47 to $1.49 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 12:49 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 50,000 | $1.44 | $71,965.00 |
DisclosureSEC source: 0001062822-26-000031 · form4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,704,186 F1 · price: Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.425 to $1.455 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| February 18, 2026 Filed Feb 18, 2026 21:30 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 133,688 | $1.32 | $176,468.16 |
DisclosureSEC source: 0001062822-26-000029 · form4.xml · nonDerivative · entry 3 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,654,186 F3 · price: Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.315 to $1.32 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:30 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 76,857 | $1.31 | $100,544.33 |
DisclosureSEC source: 0001062822-26-000029 · form4.xml · nonDerivative · entry 2 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,520,498 F2 · price: Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.295 to $1.31 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 21:30 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 57,952 | $1.31 | $75,876.55 |
DisclosureSEC source: 0001062822-26-000029 · form4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,443,641 F1 · price: Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.31 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:25 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantSeries B Convertible Preferred Stock | 367,145.12 | $65.00 | $23,864,432.80 |
DisclosureSEC source: 0001193125-26-037644 · ownership.xml · nonDerivative · entry 4 Invus Global Management, LLC · CIK 0002005369 · Director · 10% owner Siren, L.L.C. · CIK 0002005245 · Director · 10% owner DEBBANE RAYMOND · CIK 0001053890 · Director Artal Participations S.a r.l. · CIK 0002048403 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 367,145.12 F3 · kind: On January 29, 2026, Artal Participations S.a r.l. entered into a preferred stock purchase agreement (the "Preferred Purchase Agreement") with the Issuer pursuant to which Artal Participations S.a r.l. agreed to purchase 367,145.12 shares of Series B Convertible Preferred Stock, par value $0.01 per share (the "Preferred Stock") of the Issuer at a price of $65.00 per share. The Preferred Purchase Agreement also provides Artal Participations S.a r.l. the right to purchase from the Issuer, up to an additional 94,854.88 shares of Preferred Stock at a price per share of $65.00. Each share of Preferred Stock will automatically convert into 50 shares of the Issuer's Common Stock upon receipt of shareholder approval and the satisfaction of certain other conditions; however, absent the satisfaction of such conditions, the shares are not convertible. The purchase closed on February 2, 2026. F4 · ownership.nature: These securities are directly held by Artal Participations S.a r.l. F9 · ownership.nature: The sole shareholder of Artal Participations S.a r.l. is Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F15 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:25 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 1,538,462 | $1.30 | $2,000,000.60 |
DisclosureSEC source: 0001193125-26-037644 · ownership.xml · nonDerivative · entry 3 Invus Global Management, LLC · CIK 0002005369 · Director · 10% owner Siren, L.L.C. · CIK 0002005245 · Director · 10% owner DEBBANE RAYMOND · CIK 0001053890 · Director Artal Participations S.a r.l. · CIK 0002048403 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 1,538,462 F2 · kind: On February 2, 2026, Avicenna Life Sci Master Fund LP purchased 1,538,462 shares of Common Stock as part of the Issuer's underwritten public offering. F6 · ownership.nature: These securities are directly held by Avicenna Life Sci Master Fund LP F11 · ownership.nature: The general partner of Avicenna Life Sci Master Fund LP is Avicenna Life Sci Master GP LLC. The managing member of Avicenna Life Sci Master GP LLC is Ulys, L.L.C. The managing member of Ulys, L.L.C. is Mr. Raymond Debbane. F15 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:25 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantCommon Stock | 3,846,154 | $1.30 | $5,000,000.20 |
DisclosureSEC source: 0001193125-26-037644 · ownership.xml · nonDerivative · entry 2 Invus Global Management, LLC · CIK 0002005369 · Director · 10% owner Siren, L.L.C. · CIK 0002005245 · Director · 10% owner DEBBANE RAYMOND · CIK 0001053890 · Director Artal Participations S.a r.l. · CIK 0002048403 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 7,362,368 F1 · kind: On January 29, 2026, Artal Participations S.a r.l. entered into a purchase agreement with the Issuer pursuant to which Artal Participations S.a r.l. agreed to purchase 22,400,000 shares of common stock par value $0.001 per share (the "Common Stock") of the Issuer at a price of $1.30 per share (the "Purchase Price"). On January 30, 2026, Artal Participations S.a r.l. assigned its right to purchase from the Issuer 3,846,154 shares of Issuer Common Stock to Invus Public Equities, L.P., and Invus Public Equities, L.P. agreed to purchase directly from the Issuer 3,846,154 shares of Issuer Common Stock at the Purchase Price. The purchase closed on February 2, 2026. F5 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F10 · ownership.nature: The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane. F15 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:25 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantCommon Stock | 18,553,846 | $1.30 | $24,119,999.80 |
DisclosureSEC source: 0001193125-26-037644 · ownership.xml · nonDerivative · entry 1 Invus Global Management, LLC · CIK 0002005369 · Director · 10% owner Siren, L.L.C. · CIK 0002005245 · Director · 10% owner DEBBANE RAYMOND · CIK 0001053890 · Director Artal Participations S.a r.l. · CIK 0002048403 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 154,734,327 F1 · kind: On January 29, 2026, Artal Participations S.a r.l. entered into a purchase agreement with the Issuer pursuant to which Artal Participations S.a r.l. agreed to purchase 22,400,000 shares of common stock par value $0.001 per share (the "Common Stock") of the Issuer at a price of $1.30 per share (the "Purchase Price"). On January 30, 2026, Artal Participations S.a r.l. assigned its right to purchase from the Issuer 3,846,154 shares of Issuer Common Stock to Invus Public Equities, L.P., and Invus Public Equities, L.P. agreed to purchase directly from the Issuer 3,846,154 shares of Issuer Common Stock at the Purchase Price. The purchase closed on February 2, 2026. F4 · ownership.nature: These securities are directly held by Artal Participations S.a r.l. F9 · ownership.nature: The sole shareholder of Artal Participations S.a r.l. is Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F15 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| December 11, 2025 Filed Feb 6, 2026 22:35 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | OtherWarrant (right to buy) · Derivative | 1,575,008 | $0.00 Strike: $7.35 | $0.00 |
DisclosureSEC source: 0001193125-26-041456 · ownership.xml · derivative · entry 2 Invus Global Management, LLC · CIK 0002005369 · 10% owner Siren, L.L.C. · CIK 0002005245 · 10% owner DEBBANE RAYMOND · CIK 0001053890 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,575,008 shares Expires 2025-12-31 F1 · ownership.direct: The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane. F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| December 11, 2025 Filed Feb 6, 2026 22:35 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | OtherCommon Stock | 1,575,008 | $7.35 | $11,576,308.80 |
DisclosureSEC source: 0001193125-26-041456 · ownership.xml · nonDerivative · entry 1 Invus Global Management, LLC · CIK 0002005369 · 10% owner Siren, L.L.C. · CIK 0002005245 · 10% owner DEBBANE RAYMOND · CIK 0001053890 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,825,013 F1 · ownership.direct: The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane. F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 20:20 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 89,312 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-016458 · form4.xml · derivative · entry 2 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,312 Underlying: Common Stock · 89,312 shares Expires not disclosed F2 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 20:20 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 103,806 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001127602-25-016458 · form4.xml · derivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,806 Underlying: Common Stock · 103,806 shares Expires 2035-06-03 F1 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date. Read SEC document |
| May 13, 2025 Filed May 13, 2025 21:48 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 36,810 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014139 · form4.xml · derivative · entry 3 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,810 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| May 13, 2025 Filed May 13, 2025 21:48 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 36,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014139 · form4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,385,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 21:39 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 1,600,000 | $41.65 | $66,640,000.00 |
DisclosureSEC source: 0000950170-24-135847 · ownership.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Siren, L.L.C. · CIK 0002005245 · 10% owner Invus Global Management, LLC · CIK 0002005369 · 10% owner DEBBANE RAYMOND · CIK 0001053890 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,250,005 F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:31 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 149 | $40.98 | $6,106.02 |
DisclosureSEC source: 0000950170-24-131539 · ownership.xml · nonDerivative · entry 5 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Siren, L.L.C. · CIK 0002005245 · 10% owner Invus Global Management, LLC · CIK 0002005369 · 10% owner DEBBANE RAYMOND · CIK 0001053890 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,850,005 F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:31 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 30,683 | $40.14 | $1,231,584.94 |
DisclosureSEC source: 0000950170-24-131539 · ownership.xml · nonDerivative · entry 4 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Siren, L.L.C. · CIK 0002005245 · 10% owner Invus Global Management, LLC · CIK 0002005369 · 10% owner DEBBANE RAYMOND · CIK 0001053890 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,850,154 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.960 to $40.940 per share, inclusive. The Reporting Persons undertake to provide to Scholar Rock Holding Corp, any security holder of Scholar Rock Holding Corp, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:31 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 126,442 | $39.51 | $4,995,774.00 |
DisclosureSEC source: 0000950170-24-131539 · ownership.xml · nonDerivative · entry 3 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Siren, L.L.C. · CIK 0002005245 · 10% owner Invus Global Management, LLC · CIK 0002005369 · 10% owner DEBBANE RAYMOND · CIK 0001053890 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,880,837 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.960 to $39.955 per share, inclusive. The Reporting Persons undertake to provide to Scholar Rock Holding Corp, any security holder of Scholar Rock Holding Corp, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:31 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 43,887 | $38.43 | $1,686,669.57 |
DisclosureSEC source: 0000950170-24-131539 · ownership.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Siren, L.L.C. · CIK 0002005245 · 10% owner Invus Global Management, LLC · CIK 0002005369 · 10% owner DEBBANE RAYMOND · CIK 0001053890 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,007,279 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.960 to $38.955 per share, inclusive. The Reporting Persons undertake to provide to Scholar Rock Holding Corp, any security holder of Scholar Rock Holding Corp, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:31 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 208,272 | $37.63 | $7,837,504.46 |
DisclosureSEC source: 0000950170-24-131539 · ownership.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Siren, L.L.C. · CIK 0002005245 · 10% owner Invus Global Management, LLC · CIK 0002005369 · 10% owner DEBBANE RAYMOND · CIK 0001053890 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,051,166 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.960 to $37.955 per share, inclusive. The Reporting Persons undertake to provide to Scholar Rock Holding Corp, any security holder of Scholar Rock Holding Corp, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| August 08, 2024 Filed Aug 9, 2024 20:30 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | SaleCommon Stock | 260,873 | $0.19 | $50,009.35 |
DisclosureSEC source: 0000950170-24-094800 · ownership.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Siren, L.L.C. · CIK 0002005245 · 10% owner Invus Global Management, LLC · CIK 0002005369 · 10% owner DEBBANE RAYMOND · CIK 0001053890 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,317,565 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.18 to $0.1978 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| August 07, 2024 Filed Aug 9, 2024 20:30 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | SaleCommon Stock | 61,488 | $0.18 | $11,196.96 |
DisclosureSEC source: 0000950170-24-094800 · ownership.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Siren, L.L.C. · CIK 0002005245 · 10% owner Invus Global Management, LLC · CIK 0002005369 · 10% owner DEBBANE RAYMOND · CIK 0001053890 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,578,438 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.175 to $0.1855 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| August 06, 2024 Filed Aug 7, 2024 20:30 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | SaleCommon Stock | 55,732 | $0.18 | $10,187.81 |
DisclosureSEC source: 0000950170-24-092864 · ownership.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Siren, L.L.C. · CIK 0002005245 · 10% owner Invus Global Management, LLC · CIK 0002005369 · 10% owner DEBBANE RAYMOND · CIK 0001053890 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,639,926 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.18 to $0.1907 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 20:30 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | SaleCommon Stock | 164,523 | $0.19 | $30,996.13 |
DisclosureSEC source: 0000950170-24-092864 · ownership.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Siren, L.L.C. · CIK 0002005245 · 10% owner Invus Global Management, LLC · CIK 0002005369 · 10% owner DEBBANE RAYMOND · CIK 0001053890 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,695,658 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.187 to $0.1891 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| August 02, 2024 Filed Aug 5, 2024 20:53 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | SaleCommon Stock | 286,200 | $0.20 | $57,354.48 |
DisclosureSEC source: 0000950170-24-090910 · ownership.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Siren, L.L.C. · CIK 0002005245 · 10% owner Invus Global Management, LLC · CIK 0002005369 · 10% owner DEBBANE RAYMOND · CIK 0001053890 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,860,181 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.20 to $0.2025 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:53 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | SaleCommon Stock | 63,564 | $0.22 | $13,742.54 |
DisclosureSEC source: 0000950170-24-090910 · ownership.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Siren, L.L.C. · CIK 0002005245 · 10% owner Invus Global Management, LLC · CIK 0002005369 · 10% owner DEBBANE RAYMOND · CIK 0001053890 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,146,381 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.215 to $0.2185 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| July 30, 2024 Filed Jul 30, 2024 21:16 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | SaleCommon Stock | 756,835 | $0.22 | $167,184.85 |
DisclosureSEC source: 0000950170-24-088020 · ownership.xml · nonDerivative · entry 3 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Siren, L.L.C. · CIK 0002005245 · 10% owner Invus Global Management, LLC · CIK 0002005369 · 10% owner DEBBANE RAYMOND · CIK 0001053890 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,209,945 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.215 to $0.24 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| July 29, 2024 Filed Jul 30, 2024 21:16 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | SaleCommon Stock | 363,949 | $0.24 | $85,637.20 |
DisclosureSEC source: 0000950170-24-088020 · ownership.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Siren, L.L.C. · CIK 0002005245 · 10% owner Invus Global Management, LLC · CIK 0002005369 · 10% owner DEBBANE RAYMOND · CIK 0001053890 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,966,780 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.23 to $0.241 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 21:16 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | SaleCommon Stock | 258,335 | $0.24 | $62,439.57 |
DisclosureSEC source: 0000950170-24-088020 · ownership.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Siren, L.L.C. · CIK 0002005245 · 10% owner Invus Global Management, LLC · CIK 0002005369 · 10% owner DEBBANE RAYMOND · CIK 0001053890 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,330,729 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.2451 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| May 13, 2024 Filed May 13, 2024 20:02 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 36,810 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-015079 · form4.xml · derivative · entry 2 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,810 Underlying: Common Stock · 36,810 shares Expires not disclosed F2 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| May 13, 2024 Filed May 13, 2024 20:02 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 44,906 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001127602-24-015079 · form4.xml · derivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,906 Underlying: Common Stock · 44,906 shares Expires 2034-05-13 F1 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date. Read SEC document |
| April 28, 2024 Filed Apr 29, 2024 20:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 8,032 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013555 · form4.xml · derivative · entry 3 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,032 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 28, 2024 Filed Apr 29, 2024 20:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 8,032 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013555 · form4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,348,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2023 Filed Oct 12, 2023 20:01 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 148,820 | $1.03 | $153,805.47 |
DisclosureSEC source: 0001127602-23-025798 · form4.xml · nonDerivative · entry 4 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,340,847 F3 · price: This transaction was executed in multiple trades at prices ranging from $1.02 to $1.07 per share. The price reported above reflects the weighted average purchase price of such trades. Mr. Debbane hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which this transaction was effected. Read SEC document |
| October 11, 2023 Filed Oct 12, 2023 20:01 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 342,874 | $1.08 | $370,783.94 |
DisclosureSEC source: 0001127602-23-025798 · form4.xml · nonDerivative · entry 3 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,192,027 F2 · price: This transaction was executed in multiple trades at prices ranging from $1.06 to $1.12 per share. The price reported above reflects the weighted average purchase price of such trades. Mr. Debbane hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 10, 2023 Filed Oct 12, 2023 20:01 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 508,306 | $1.14 | $579,367.18 |
DisclosureSEC source: 0001127602-23-025798 · form4.xml · nonDerivative · entry 2 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 849,153 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.09 to $1.19 per share. The price reported above reflects the weighted average purchase price of such trades. Mr. Debbane hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which this transaction was effected. Read SEC document |
| May 21, 2023 Filed May 22, 2023 20:03 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 9,302 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016431 · form4.xml · derivative · entry 3 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,302 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| May 21, 2023 Filed May 22, 2023 20:03 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 9,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016431 · form4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 340,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:12 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 835 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028724 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Former Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,387 Read SEC document |
| April 28, 2023 Filed Apr 28, 2023 20:22 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 12,658 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001127602-23-013782 · form4.xml · derivative · entry 2 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,658 Underlying: Common Stock · 12,658 shares Expires 2033-04-28 F3 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date. Read SEC document |
| April 28, 2023 Filed Apr 28, 2023 20:22 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 8,032 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-013782 · form4.xml · derivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,032 Underlying: Common Stock · 8,032 shares Expires not disclosed F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:05 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 2,053 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023259 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,552 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 21:22 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 5,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-000925 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,499 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.